Program/Compound NX-217 Β· EU5 Launch
Phase III

πŸ‡¬πŸ‡§ United Kingdom

Drill-down: 5 tasks Β· 2 risks Β· launch 30 May 2026

Status

Delayed

Launch slip: 1 mo

Readiness

24%

Baseline 5Y

€402.5M

Adjusted 5Y

€392.2M

-€10.3M vs baseline

Plan

Task
Sept 25
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Today
Regulatory
Market Access
Supply
Medical
Marketing
Baseline On track In progress Delayed Gating task

Risks (2)

High
Owen Briggs

NICE OS extrapolation challenge likely β€” committee may request additional data cut.

High
James Patel

UK Launch Supply (depends on DE) delayed by 1 month β€” cascade from EMA Filing & Approval

Files

Global Launch Playbook v3.2.pdf4.2 MB
UK Supply Chain MOU.pdf1.8 MB
Global HCP Campaign Toolkit.zip120.6 MB
NICE Cost-Effectiveness Model v4.xlsx8.6 MB
Master Messaging Framework v2.1.pdf3.4 MB
Phase III Topline Results β€” NX-217.pdf6.7 MB
EU5 Patient Journey Research.pdf14.2 MB
Global Brand Visual Identity.zip210.3 MB